These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 2684592)

  • 1. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Brogden RN; Sorkin EM
    Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.
    Wadworth AN; Fitton A
    Drugs; 1991 Apr; 41(4):647-64. PubMed ID: 1711964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of rectal formulations: enemas.
    Campieri M; Gionchetti P; Belluzzi A; Brignola C; Tampieri M; Iannone P; Petronelli A; Miglioli M; Barbara L
    Scand J Gastroenterol Suppl; 1990; 172():63-5. PubMed ID: 2353173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N; Weir DG; Kelleher D
    Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
    Rao SS; Cann PA; Holdsworth CD
    Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
    Prakash A; Markham A
    Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
    Nakshabendi IM; Duncan A; Russell RI
    Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
    Donald IP; Wilkinson SP
    Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesalazine in childhood inflammatory bowel disease.
    Barden L; Lipson A; Pert P; Walker-Smith JA
    Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of mesalazine microgranules on experimental colitis].
    Nakamaru K; Sugai T; Hongyo T; Sato M; Taniguchi S; Tanaka Y; Kawase S
    Nihon Yakurigaku Zasshi; 1994 Oct; 104(4):303-11. PubMed ID: 7959421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesalazine: a global safety evaluation.
    Brimblecombe R
    Scand J Gastroenterol Suppl; 1990; 172():66. PubMed ID: 1972297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of mesalazine enemas in active and quiescent ulcerative colitis.
    van Bodegraven AA; Boer RO; Lourens J; Tuynman HA; Sindram JW
    Aliment Pharmacol Ther; 1996 Jun; 10(3):327-32. PubMed ID: 8791959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of rectal formulations: suppositories.
    Williams CN
    Scand J Gastroenterol Suppl; 1990; 172():60-2. PubMed ID: 2191425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Giaffer MH; O'Brien CJ; Holdsworth CD
    Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis.
    Mantzaris GJ; Hatzis A; Petraki K; Spiliadi C; Triantaphyllou G
    Dis Colon Rectum; 1994 Jan; 37(1):58-62. PubMed ID: 8287749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer pharmacologic agents for the therapy of inflammatory bowel disease.
    Ruderman WB
    Med Clin North Am; 1990 Jan; 74(1):133-53. PubMed ID: 2404172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mesalazine enema for ulcerative colitis.
    Drug Ther Bull; 1994 May; 32(5):38-9. PubMed ID: 7635028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.